TARO NYSE
Taro Pharmaceutical Industries Ltd.
1W: +0.5%
1M: +1.1%
3M: +1.9%
1Y: +6.1%
3Y: -41.2%
5Y: -51.4%
$42.98
Last traded 2024-06-21 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$2.2B
+1.2% ▲
5Y CAGR: +0.2%
Total Liabilities
$369M
-8.8% ▼
5Y CAGR: +10.5%
Shareholders Equity
$1.8B
+3.6% ▲
5Y CAGR: -1.2%
Cash & Investments
$879M
+3.4% ▲
5Y CAGR: -3.5%
Total Debt
$0
-100.0% ▼
Net Debt
-$363M
-137.9% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $513M | $605M | $251M | $154M | $363M |
| Short-Term Investments | $595M | $418M | $570M | $696M | $516M |
| Cash & ST Investments | $1.1B | $1.0B | $821M | $850M | $879M |
| Net Receivables | $262M | $253M | $292M | $242M | $177M |
| Inventory | $153M | $180M | $210M | $227M | $205M |
| Other Current Assets | $9M | $13M | $14M | $12M | $42M |
| Total Current Assets | $1.5B | $1.5B | $1.3B | $1.3B | $1.3B |
| Property, Plant & Equip. | $210M | $206M | $200M | $190M | $218M |
| Goodwill & Intangibles | $29M | $27M | $72M | $93M | $17M |
| Long-Term Investments | $460M | $557M | $435M | $405M | $458M |
| Other Non-Current Assets | $4M | $4M | $7M | $83M | $82M |
| Total Non-Current Assets | $809M | $936M | $838M | $799M | $859M |
| Total Assets | $2.3B | $2.4B | $2.2B | $2.1B | $2.2B |
| — Liabilities — | |||||
| Accounts Payable | $29M | $61M | $68M | $68M | $45M |
| Short-Term Debt | $2M | $2M | $2M | $2M | $0 |
| Deferred Revenue | $237K | $8M | $6M | $903K | $0 |
| Other Current Liabilities | $192M | $606M | $356M | $314M | $316M |
| Total Current Liabilities | $223M | $676M | $432M | $386M | $361M |
| Long-Term Debt | -$4M | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $3M | -$1M | -$919K | -$616K | $8M |
| Total Non-Current Liabilities | $9M | $35M | $33M | $19M | $8M |
| Total Liabilities | $231M | $711M | $465M | $405M | $369M |
| — Equity — | |||||
| Common Stock | $679K | $679K | $680K | $680K | $1.8B |
| Retained Earnings | $2.7B | $2.3B | $2.4B | $2.4B | $0 |
| Accumulated OCI | -$163M | -$152M | -$169M | -$175M | $0 |
| Total Stockholders Equity | $2.1B | $1.7B | $1.7B | $1.7B | $1.8B |
| Total Liabilities & Equity | $2.3B | $2.4B | $2.2B | $2.1B | $2.2B |
| — Key Metrics — | |||||
| Total Debt | $2M | $2M | $2M | $2M | $0 |
| Net Debt | -$512M | -$603M | -$249M | -$153M | -$363M |
| Total Investments | $1.1B | $976M | $1.0B | $1.1B | $974M |